$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
The hallmark of many cardiac diseases in human is a systolic and/or diastolic functional impairment of the left ventricle (LV). For the detection of structural abnormalities, the diagnosis, and the management of systolic heart failure as well as the evaluation of diastolic function in patients with symptoms of heart failure, echocardiography is used as a fundamental assessment modality.
Since the symptoms are unspecific and more than one third of patients with the clinical syndrome of heart failure may not suffer from the actual heart failure, it is important to find an objective echocardiographic correlate for the patient's clinical presentation1. Furthermore, some symptoms which are occult in the resting or static state may occur under conditions of activity or stress. In patients with coronary artery disease, already minor changes in coronary perfusion can lead to regional wall motion abnormalities. However, these subtle changes cannot be evaluated using conventional echocardiography as alterations of cardiac disease can be hidden in unstressed hearts. To gain a deeper understanding of the cardiac physiopathology, stress echocardiography provides a dynamic evaluation of myocardial structure and function under conditions of exercise or pharmacological induced stress, permitting matching symptoms with cardiac findings2. Also, in small animals, this method represents a non-invasive reliable in-vivo tool3,4,5. In-line with humans, stress reaction of the myocardium can be induced via pharmacological agents in mice and rats. Dobutamine is a frequently used drug and dobutamine stress echocardiography is widely performed in humans6,7 but only sometimes used in small animal models to assess cardiac stress reaction8,9,10,11. Dobutamine is a synthetical catecholamine with a predominantly β1-agonistic effect resulting in positive inotropy and chronotropy of the heart. To achieve a correct translation from human to mouse, the technology and the conceptual framework of echocardiography, technical limitations related to e.g., the small size and rapid heart rate in the mouse must be considered. The human target heart rate in dobutamine stress echocardiography is [(220-age) x 0.85] resulting in an average heart rate increase of about 150 ± 10% in healthy volunteers12,13. For mice, such a formula is missing. The ejection fraction (EF) is described to be increased by stress echocardiography in humans by 5-20%12,14. The EF in mice is, depending on the heart rate, reported between 58 ± 11% (< 450 bpm) and 71 ± 11% (≥ 450 bpm) and changes by nearly 20% with higher heart rates4. The main mechanism in mice to increase the cardiac output is an increase in the heart rate. Partly responsible for this mechanism is the Bowditch effect or staircase phenomenon, a frequency-dependent calcium-mediated positive-inotropic cardiac response, that is more pronounced in mice than in humans15,16. In addition, (stress) echocardiography underlies intra- and interobserver variability. Therefore, a highly standardized procedure is indispensable17,18.
Here we present the detailed procedure of dobutamine stress echocardiography to acquire standardized images to unravel subtle changes in cardiac function in mice in models of health and disease. Key components include adequate anesthesia, adequate heart rate monitoring and possible pitfalls in stress-induced imaging in mice. Key parameters are the evaluation of systolic and diastolic function including consideration of the LVEF. Because mice are resistant to afterload-induced cardiac dysfunction17, this protocol may add valuable information for the use in models of valvular heart disease as well.